AUTHORS
Karan L. Chohan, MD, Cao Cuong Cao Le, PhD, MSc2, Jinsheng Weng, MD, PhD3, Jingwei Liu Sr4, Federico Mario Aletti5, Sushanth Gouni, MD6, Luis Malpica, MD7, Ranjit Nair, MD8, Neha Akkad, MD9, Paolo Strati, MD10, Luis E. Fayad, MD11, Sairah Ahmed, MD12, Ayushi Chauhan, MD13, Dai Chihara, MD, PhD14, Anath Christopher Lionel, MD, PhD15, Frederick B. Hagemeister, MD16, Chijioke C Nze, MD, MPH17, Fateeha Furqan, MBBS18, Mark P Hamilton, MD19, Robert Harkins, MD, MS20, Yiming Chen21, Swapna Binoy22, Jason Westin, MD, MS, FACP, FASCO23, Lei Feng, MS24, Ryan Sun25, Christopher R. Flowers Jr, MD, MS26, Francisco Vega Sr, MD PHD27, Swaminathan P. Iyer, MD28, Sattva S Neelapu Sr, MD29
AFFILIATIONS
1 The University of Texas MD Anderson Cancer Center, Houston, United States
2 The University of Texas MD Anderson Cancer Center, Houston, United States
3 The University of Texas MD Anderson Cancer Center, Houston, United States
4 The University of Texas MD Anderson Cancer Center, Houston, United States
5 The University of Texas MD Anderson Cancer Center, Houston, United States
6 The University of Texas MD Anderson Cancer Center, Houston, United States
7 The University of Texas MD Anderson Cancer Center, Houston, United States
8 The University of Texas MD Anderson Cancer Center, Houston, United States
9 The University of Texas MD Anderson Cancer Center, Houston, United States
10 The University of Texas MD Anderson Cancer Center, Houston, United States
11 The University of Texas MD Anderson Cancer Center, Houston, United States
12 The University of Texas MD Anderson Cancer Center, Houston, United States
13 The University of Texas MD Anderson Cancer Center, Houston, United States
14 The University of Texas MD Anderson Cancer Center, Houston, United States
15 The University of Texas MD Anderson Cancer Center, Houston, United States
16 The University of Texas MD Anderson Cancer Center, Houston, United States
17 The University of Texas MD Anderson Cancer Center, Houston, United States
18 The University of Texas MD Anderson Cancer Center, Houston, United States
19 The University of Texas MD Anderson Cancer Center, Houston, United States
20 The University of Texas MD Anderson Cancer Center, Houston, United States
21 The University of Texas MD Anderson Cancer Center, Houston, United States
22 The University of Texas MD Anderson Cancer Center, Houston, United States
23 The University of Texas MD Anderson Cancer Center, Houston, United States
24 The University of Texas MD Anderson Cancer Center, Houston, United States
25 The University of Texas MD Anderson Cancer Center, Houston, United States
26 The University of Texas MD Anderson Cancer Center, Houston, United States
27 The University of Texas MD Anderson Cancer Center, Houston, United States
28 The University of Texas MD Anderson Cancer Center, Houston, United States
29 The University of Texas MD Anderson Cancer Center, Houston, United States
ABSTRACT
Background and Significance: T/NK-cell malignancies comprise 10-15% of non-Hodgkin lymphomas and include aggressive cytotoxic subtypes with 5-year survival below 20%, underscoring an urgent need for effective therapies. While CAR T-cell therapy has transformed treatment of relapsed/refractory (R/R) B-cell lymphomas, its development for T/NK-cell malignancies has been limited by the risk of T-cell aplasia when targeting pan-T-lineage antigens and by fratricide, which impairs CAR T expansion and efficacy.
CD94 (KLRD1) is a C-type lectin receptor expressed on subsets of normal NK cells (40-70%) and γδ T cells (40-60%) and a minority of CD8+ T cells (<10%). We and others have previously demonstrated that CD94 is otherwise absent from healthy non-hematopoietic tissues but is highly expressed in cytotoxic T/NK neoplasms, including extranodal NK/T-cell lymphoma (TCL), hepatosplenic TCL, primary cutaneous CD8+ aggressive epidermotropic TCL, subcutaneous panniculitis-like TCL, monomorphic epitheliotropic intestinal TCL, enteropathy-associated TCL, aggressive NK-cell leukemia, and T- and NK-cell large granular lymphocytic (LGL) leukemias, among others (Le et al. ASH 2025). In a phase 1 clinical trial, treatment with DR-01, an anti-CD94 monoclonal antibody, was well tolerated with promising efficacy (Horowitz et al. ASH 2025; Marchi et al. ASH 2025).
JV-394 is an autologous second-generation (4-1BB/CD3ζ) anti-CD94 CAR T-cell product co-expressing a truncated BCMA (tBCMA) safety switch. In our preclinical studies (Le et al. ASH 2025), JV-394 demonstrated potent antitumor activity with eradication of disseminated NK leukemia and patient-derived hepatosplenic TCL and NK/TCL xenografts. Importantly, neither significant CAR T-cell fratricide nor pan-T-cell aplasia was observed in in vitro co-cultures or in humanized mice. Furthermore, anti-BCMA agents rapidly cleared CAR T cells in vitro and in vivo, supporting tBCMA as a functional safety switch.
Study Design and Methods: This single-arm, single-center, open-label phase 1 study (NCT07382817; MD Anderson Cancer Center, Houston, TX, USA; recruiting) is evaluating the safety and efficacy of JV-394 in adults with R/R CD94+ T/NK-cell malignancies, with dose escalation and expansion cohorts.
Key inclusion criteria: R/R T/NK-cell malignancies after ≥1 systemic therapy or intolerance to standard therapy; ≥50% of tumor cells CD94+ by flow cytometry or IHC; ECOG PS 0-1. Key exclusion criteria: aggressive NK-cell leukemia; indolent T/NK-cell malignancies such as T- or NK-LGL leukemia; peripheral blood tumor cells ≥1% of lymphocytes by flow cytometry; active CNS lymphoma; autologous transplant <6 weeks or allogeneic transplant <3 months prior; active graft-versus-host disease.
The primary objective is to determine safety and identify the MTD or RP2D. The secondary objective is efficacy at the MTD/RP2D; secondary endpoints include ORR (CR+PR) and CR rate by Lugano or Olsen criteria, DOR, PFS, and OS. Up to 18 patients will be enrolled in dose escalation and 15 in expansion at the MTD/RP2D. A Bayesian optimal interval (BOIN) design with a 3+3 run-in will guide dose escalation.
After eligibility confirmation, patients will undergo leukapheresis, with optional bridging therapy permitted before conditioning. JV-394 will be produced using a 3-day rapid manufacturing process. Conditioning with cyclophosphamide and fludarabine will be given days -5 to -3, followed by a single JV-394 infusion on day 0. Three flat dose levels will be tested (10, 20, and 40×106 CAR+ T cells); if a DLT occurs at dose level 1, dose level -1 (5 × 106) will be evaluated. DLTs will be assessed through day 28.
AEs will be graded by CTCAE v5.0, with CRS, ICANS, and IEC-HS graded by ASTCT criteria and managed per institutional CARTOX guidelines. Patients will be monitored daily at a healthcare facility for ≥7 days after infusion, at least 3 times during week 2, and weekly during weeks 3-4. Elimination of JV-394 via the tBCMA safety switch using commercially available BCMA-directed agents (teclistamab or belantamab mafodotin) may be considered for refractory JV-394-attributed AEs.
Exploratory objectives are to assess the cellular kinetics and pharmacodynamics of JV-394 and biomarkers of response, resistance, and toxicity by comprehensive genomic, transcriptomic, proteomic, and functional profiling of serial blood samples, tumor samples, and CAR T-cell products.
DISCLOSURES
Karan L. Chohan, MD: No relevant conflicts of interest to declare.